Top 10 Medical Stocks To Watch Right Now

Image source: Getty Images.

What happened

Shares of Insulet Corporation(NASDAQ:PODD), a medical device company primarily focused on diabetes,rose by as much as 11% in afternoon trading on Friday.

So what

The drug delivery specialist didn’t release any news on Friday that could justify its big move.Instead, Insulet’s stock appears to be rising in response to goodnews that was released by one of the company’s partners.

DexCom (NASDAQ:DXCM), a diabetes-focused company that makes continuous glucose monitors, announced on Thursday evening that theCenters for Medicare & Medicaid Services (CMS) has officially decided to cover its G5 Mobilesystem.

DexCom’s CEO Kevin Sayer was thrilled with the news, stating, “This landmark CMS Ruling will make available the most important technology in diabetes management to theMedicarepopulation.”

Top 10 Medical Stocks To Watch Right Now: Glu Mobile Inc.(GLUU)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows that Zynga Inc peaked after the IPO, but has at least been less volatile since then compared to the performance of remaining small cap mobile gaming stockGlu Mobile Inc (NASDAQ: GLUU) and large capActivision Blizzard:

  • [By Peter Graham]

    Small cap mobile game stock Glu Mobile Inc (NASDAQ: GLUU) reportedQ2 2017 earnings after the market closed on Tuesday. Revenue grew 42% year over year to $68.7 million while bookingsincreased 62% to$82.5 million (whichexceed high end of guidance) and Design Home peaked as the#17 top grossing game on U.S. App Store for iPhone. The net loss was $23.568 million versus a net loss of $17.949 million. The Company also raised 2017 full year bookings guidance to a range of $307 million to $312 million.

  • [By Peter Graham]

    A long term performance chart shows that Zynga Inc largely moving sideways for the pastthree years or sowhile remaining small cap mobile gaming stockGlu Mobile Inc (NASDAQ: GLUU) has underperformed andlarge capActivision Blizzard continues to have a good run:

  • [By Lee Jackson]

    Glu Mobile Inc. (NASDAQ: GLUU) was started with a Neutral rating and a $2.30 price objective at Mizuho. The Wall Street estimate is$2.56. The 52-week range is $1.73 to $4.00, and the stock closed yesterday at $2.10.

Top 10 Medical Stocks To Watch Right Now: Mitsubishi Corporation (MSBHY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Renault Nissan (OTC:RNSDF) (NSANY)/Mitsubishi (OTCPK:MSBHY) (MMTOF)

    On December 20, Green Car Reports reported: “Mitsubishi electric cars to use Nissan-Renault platforms.” Remember Mitsubishi has the US$22,995 all-electric 16 kWh iMiEV coming out in 2017.

  • [By SEEKINGALPHA.COM]

    Mitsubishi (OTCPK:MSBHY)

    Earlier in 2016, Mitsubishi released its 2017 i-MiEV. It is fully electric, with a 16 kWh lithium-ion battery pack and a range of 62 miles. Basically just a short trips car, as the range is really very low. Mitsubishi also has its popular plug in hybrid Outlander model that sells quite well. As stated last month, the company announced “plans to launch a compact EV with 250-mile range by 2020”. Mitsubishi is currently ranked 7th in global EV sales.

Top 10 Medical Stocks To Watch Right Now: Aphria Inc. (APHQF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Some of you may have seen the joint press release this morning from Aphria Inc. (OTCQB:APHQF) and Liberty Health Sciences Inc. (OTCPK:SCQBD) regarding their response to TMX Group’s “regulatory engagement.” Some people contacted us asking questions like how are the two companies related?, and more. Don’t worry – we’ve got you covered!

  • [By Keith Speights]

    There are plenty of reasons for investors to like three marijuana stocks in particular — GW Pharmaceuticals (NASDAQ:GWPH), Insys Therapeutics (NASDAQ:INSY), and Aphria (NASDAQOTH:APHQF). In fact, there are at least 661 million reasons. That’s the amount of cash in U.S. dollars that the three companies have combined. Here’s why the cash stockpiles held by GW, Insys, and Apria are important.

  • [By Keith Speights]

    As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?

Top 10 Medical Stocks To Watch Right Now: Envision Healthcare Holdings, Inc.(EVHC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Even on a day like today, somebody had to be the worst performer in the S&P 500, and today that somebody is Envision Healthcare (EVHC), which missed earnings forecasts last night.

  • [By Paul Ausick]

    Envision Healthcare Corp. (NYSE: EVHC) dropped about 9.3% Tuesday to post a new 52-week low of $43.22 after closing Monday at $47.67. The 52-week high is $74.75. Volume of around 10 million shares traded was about six times the daily average. The company had no specific news.

  • [By Lisa Levin]

    Envision Healthcare Holdings Inc (NYSE: EVHC) shares shot up 211 percent to $70.15. Envision Healthcare and Amsurg Corp (NASDAQ: AMSG) reported the completion of their merger.

Top 10 Medical Stocks To Watch Right Now: Veeco Instruments Inc.(VECO)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    VECO (NASDAQ:VECO) contributed 1.16% to the Fund’s quarterly return, nearly equaling AAN’s contribution in the quarter. VECO appreciated over 48% in the quarter due to an acceleration of orders for its key MOCVD tools. These tools are the main manufacturing equipment used to produce LEDs, whether they are for display screens or, increasingly, for lighting products. We estimate that VECO currently has roughly 80% global market share for MOCVD tools used to make LEDs.

Top 10 Medical Stocks To Watch Right Now: General Motors Company(GM)

Advisors’ Opinion:

  • [By Paul Ausick]

    Among the Detroit Three the outlook is decidedly mixed. According to researchers at Kelley Blue Book (KBB), General Motors Co. (NYSE: GM) is forecast to sell 249,000 units, up 8.6% compared with November of 2015. GM’s U.S. market share is expected to reach 18.2%, up 0.7 percentage point year over year. Ford Motor Co. (NYSE: F) is touted to post a sales gain of just 0.1% with 189,000 units for a market share of 13.6%, down 0.6 point year over year. Fiat Chrysler Automobiles NV (NYSE: FCAU) is forecast to see unit sales drop 4.5% year over year to 168,000 and a market share of 12.3%, down 1.1 percentage points.

  • [By WWW.THESTREET.COM]

    IBM was among a number of companies Trump hit on the campaign trail for shipping jobs overseas. He accused the company of laying off 500 workers in Minneapolis and moving their jobs to India at a Minnesota rally just a day before the election. He made similar attacks against Ford (F) , Apple (AAPL) and General Motors (GM) , among others.

  • [By Lisa Levin]

    General Motors Company (NYSE: GM) reported better-than-expected results for its fourth quarter.

    GM reported Q4 adjusted earnings of $1.28 per share on revenue of $43.9 billion, Analysts were expecting earnings of $1.17 per share on revenue of $41.5 billion.

  • [By Michael A. Robinson]

    If you still find the idea of self-driving cars hard to believe, consider this…

    Uberbegan testing driverless cars inPittsburghearlier this year, and the Obama administration has endorsed the push to develop these vehicles.Alphabet Inc.(Nasdaq:GOOGL)has fielded a fleet of autonomous cars, under its Chauffeur division, that have logged a combined 2 million miles in the last four years. (Although the execs there are in the process of refocusing that division – with an announcement coming as soon as today.)Ford Motor Co. (NYSE:F)andBMW AGare working to produce driverless cars by 2021.General Motors Co. (NYSE:GM)has invested $500 million in ride-sharing startup Lyft, and the two are working on autonomous vehicles together.And in April 2015, anAudi SQ5drove 3,400 miles across the country almost entirely “hands free.”

    On that journey from San Francisco to New York, the car had to guide itself through big-city rush hours, road construction, confusing street signs, and diverse weather.

Top 10 Medical Stocks To Watch Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

Top 10 Medical Stocks To Watch Right Now: 3M Company(MMM)

Advisors’ Opinion:

  • [By Chris Lange]

    3M Company (NYSE: MMM) is set to report its second-quarter results on Tuesday. The analysts consensus estimates call for EPS of $2.54 and $7.86 billion in revenue. Shares of 3M were changing hands at $211.07 at Fridays close. The consensus price target is $205.09, and the 52-week range is $163.85 to $214.57.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded down 1.05% at $210.38. The stock’s 52-week range is $163.85 to $214.57. Volume was about 20% below the daily average of around 1.8 million. The company had no specific news.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded up 0.91% at $201.53. The stock’s 52-week range is $163.85 to $214.57. Volume was about half the daily average of around 1.8 million shares. The company had no specific news Monday.

Top 10 Medical Stocks To Watch Right Now: Kate Spade & Company(KATE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Kate Spade (KATE) caught a bounce on Wednesday when the Wall Street Journalreported that it was actively seeking a buyer. Since then, we’ve learned that the fashion accessories retailer looks set to auction itself off to the highest bidder, with the process potentially beginning next month, with bidders potentially including Coach (COH) and Michael Kors (KORS). In a note today, SunTrust Robinson Humphrey analystPamela Quintiliano and team contend that Kate Spade could fetch as much as $23 a share:

    Getty Images

    Looking at recent historical deals, we arrive at a $18-$23 potential deal range. We analyzed transactions that have been announced over the past four years and involved companies catering to a higher income customer. These deals include Southern Tide (acquired by Oxford Industries (OXM)), Joe’s Jeans (acquired by Sequential Brands Group (SQBG)), prAna (acquired by Columbia Sportswear (COLM)), The Jones Group (acquired by Sycamore Partners [private] and Juicy Couture (acquired by Authentic Brands Group [private]). The average EV/EBITDA multiple of these transactions are 12.9x (in line with KATE’s 5-year historical average of 12.1x) and implies a potential deal range of $22-$23. When taking the average of recent (F13-16) deals implies an ~10.5x EV/EBITDA multiple. When applying the ~10.5x multiples to KATE’s trailing EBITDA, we arrive at an $18- $19 potential share price.

    Shares of Kate Spade have gained 1.1% to $18.70 at 2:08 p.m. today, while Coach has declined 0.2% to $34.95, Michael Kors is little changed at $42.86, Oxford Industries has fallen 0.7% to $60.38, Columbia Sportswear has climbed 1.4% to $58.60, and Sequential Brands Group has jumped 3.7% to $4.77.

  • [By Ben Levisohn]

    Coach (COH) rose to the top of the S&P 500 today after reports that Kate Spade (KATE) had put itself up for sale caused shares of fashion-accessory retailers to rise.

  • [By Ben Levisohn]

    Time, time, time. See what’s become of Kate Spade (KATE), as investors look around at its possibilities…and don’t like what they see. That’s the takeaway today following Kate Spade’s earnings release, and update on a potential takeover.

    Getty Images

    Kate Spade reported a profit of 1 cent a share, missing forecasts for 7 cents, on sales of $271.2 million, well below analyst expectations for $299 million. And Kate Spade also updated investors on its efforts to sell itself, without offering much of an update at all.

    Cowen’s Oliver Chen and team still expect a deal to happen but lower the probability of a deal occurring to 70% from 80%. They explain why:

    …formal language on deal prospects articulates process is proceeding in a timely manner with no definitive timetable and no assurance that process will result in a transaction. We still expect a deal to happen, but do lower our probability from 80% to 70% given the likelihood that potential buyer(s) and KATE have not agreed on a clearing price in earlier rounds of negotiation. We believe a bidder such as Coach (COH) does not want to overpay, is disciplined about managing ROIC, and returns and synergies split may be more rational at an offer price in the range of $22-25. We continue to believe KATE has a long global growth runway ahead with opportunities for store growth abroad, further expansion into non-handbag categories, and supply + digital synergy potential…We rate KATE Market Perform and lower our price target to $21 (was $27). Our updated valuation is based on ~10x our FY18E adj. EBITDA or $284mm.

    Investors, however, want to see a deal get done: Shares of Kate Spade have tumbled 6.6% to $18.12 at 3:26 p.m. today, while Coach has declined 0.5% to $39.51, and Michael Kors (KORS), also rumored to be interested in an acquisition, has fallen 1.1% to $36.92.

  • [By Ben Levisohn]

    Ever since peaking in late April, Kate Spade’s (KATE) shares have been in a downward spiral so pronounced that even an amateur technical analyst like myself could draw its trend line lower. Today, however, its shares are soaring after the Wall Street Journal reported that Kate Spade was actively seeking a buyer.

    Getty Images

    Mizuho’s Betty Chen and Alex Pham run the math on a possible acquisition price:

    When we examined historical transactions in the specialty retail sector, we noticed a wide range of valuations. Select relevant transactions to consider would be ~2x EV/Sales Coach (COH) paid for Stuart Weitzman, Samsonites acquisition of Tumi at 14x EV/EBITDA, 13x EV/EBITDA for Joseph A. Banks by Mens Wearhouse (TLRD) and Kerings acquisition of Volcom for 18x EV/EBITDA. We believe potential valuation could be as high as ~2x EV/ Sales and ~14x EV/EBITDA given Kate Spade’s unique growth profile to expand to ~$4bn in revenue (from $1.4bn in FY16) and improving profitability from 12% EBIT margin TY to at least HTeens-LDD, in our view (Coach is 18.7% and Michael Kors (KORS) is 21.3%). On these two metrics, Kate Spade would be valued at $21-23…

    We believe the growth profile coupled with the brands unique appeal to Millennials and broad-based success across categories ranging from handbags to apparel and jewelry could be attractive to many buyers, including Coach, which was rumored to be evaluating the company in recent weeks.

    The news has sent shares of Kate Spade soaring: They’re up 24% at $18.03 at 2:11 p.m., a gain that has turned this year’s 18% loss as of last night into a 2% gain during afternoon trading.

    The move has also put a dent in Kate Spade’s downtrend (and now you’ll see my amateur technical analysis abilities at work):

    FactSet

    That’s one way to break a downtrend.

  • [By Lisa Levin]

    Kate Spade & Co (NASDAQ: KATE) was down, falling around 14 percent to $19.60 after it was reported the company would spend more time to negotiate the Coach Inc (NYSE: COH) offer.

Top 10 Medical Stocks To Watch Right Now: Internationa Flavors & Fragrances, Inc.(IFF)

Advisors’ Opinion:

  • [By Lee Jackson]

    International Flavors & Fragrances Inc. (NYSE: IFF) is yet another company that hit our screens witha 10% institutional owner buying stock twice last week. Winder Investment purchased a total of 70,000 shares. At $128.38per share, the total for the trade was a solid $9 million. Later in the week the company stepped in again and bought another100,000 shares at prices between $129.47 and 132.20 apiece. The total for that buy was posted at $13 million. The shares closed trading last Friday at $133.19, so some timely buys for sure. The 52-week trading range is $112.91 to $143.64. The consensus price target is $131.40.

Leave a Reply

Your email address will not be published. Required fields are marked *